Associated Papers
Association of LRRK2 p.A419V with Parkinson's Disease in East Asians and analysis of age at onset.
Lim KS et al.
Npj Parkinson's Disease, 2026
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Large-scale genetic characterization of Parkinson's disease in the African and African admixed populations.
Akçimen F et al.
Brain : a Journal of Neurology, 2025
Different Contribution of Missense and Loss-of-Function Variants to the Genetic Structure of Familial and Sporadic Meniere Disease.
Parra-Perez AM et al.
Medcomm, 2025
Clinical and functional evidence for the pathogenicity of the LRRK2 p.Arg1067Gln variant.
Lim SY et al.
Npj Parkinson's Disease, 2025
Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson's disease study.
Westenberger A et al.
Brain : a Journal of Neurology, 2024
The landscape of rare genetic variation associated with inflammatory bowel disease and Parkinson's disease comorbidity.
Kars ME et al.
Genome Medicine, 2024
A Next-Generation Sequencing Study in a Cohort of Sicilian Patients with Parkinson's Disease.
Salemi M et al.
Biomedicines, 2023
Genetic landscape of Parkinson's disease and related diseases in Luxembourg.
Landoulsi Z et al.
Frontiers in Aging Neuroscience, 2023
Impact of 100 LRRK2 variants linked to Parkinson's disease on kinase activity and microtubule binding.
Kalogeropulou AF et al.
The Biochemical Journal, 2022
Exploring the focal role of LRRK2 kinase in Parkinson's disease.
Kumar S et al.
Environmental Science and Pollution Research International, 2022
Coding and Noncoding Variation in LRRK2 and Parkinson's Disease Risk.
Lake J et al.
Movement Disorders : Official Journal of the Movement Disorder Society, 2022
Whole Exome Sequencing Study in Isolated South-Eastern Moravia (Czechia) Population Indicates Heterogenous Genetic Background for Parkinsonism Development.
Kolarikova K et al.
Frontiers in Neuroscience, 2022
Identification of LRRK2 missense variants in the accelerating medicines partnership Parkinson's disease cohort.
Bryant N et al.
Human Molecular Genetics, 2021
Fine-mapping of the non-coding variation driving the Caucasian LRRK2 GWAS signal in Parkinson's disease.
Heckman MG et al.
Parkinsonism & Related Disorders, 2021
Community-based genetic study of Parkinson's disease in Estonia.
Muldmaa M et al.
Acta Neurologica Scandinavica, 2021
Clinical and Genetic Analysis of Costa Rican Patients With Parkinson's Disease.
Torrealba-Acosta G et al.
Frontiers in Neurology, 2021
The LRRK2-RAB axis in regulation of vesicle trafficking and α-synuclein propagation.
Bae EJ et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease, 2020
Precision Health Resource of Control iPSC Lines for Versatile Multilineage Differentiation.
Hildebrandt MR et al.
Stem Cell Reports, 2019
New endemic familial parkinsonism in south Moravia, Czech Republic and its genetical background.
Bartoníková T et al.
Medicine, 2018
Exploring the functional impact of mutational drift in LRRK2 gene and identification of specific inhibitors for the treatment of Parkinson disease.
Nagarajan N et al.
Journal of Cellular Biochemistry, 2018
Study of LRRK2 variation in tauopathy: Progressive supranuclear palsy and corticobasal degeneration.
Sanchez-Contreras M et al.
Movement Disorders : Official Journal of the Movement Disorder Society, 2017
Genetic architecture differences between pediatric and adult-onset inflammatory bowel diseases in the Polish population.
Ostrowski J et al.
Scientific Reports, 2016
Additional rare variant analysis in Parkinson's disease cases with and without known pathogenic mutations: evidence for oligogenic inheritance.
Lubbe SJ et al.
Human Molecular Genetics, 2016
Genetic Mutation Analysis of Parkinson's Disease Patients Using Multigene Next-Generation Sequencing Panels.
Gorostidi A et al.
Molecular Diagnosis & Therapy, 2016
LRRK2 variation and dementia with Lewy bodies.
Heckman MG et al.
Parkinsonism & Related Disorders, 2016
Resequencing analysis of five Mendelian genes and the top genes from genome-wide association studies in Parkinson's Disease.
Benitez BA et al.
Molecular Neurodegeneration, 2016
Analysis of the genetic variability in Parkinson's disease from Southern Spain.
Bandrés-Ciga S et al.
Neurobiology of Aging, 2016
Activation of FADD-Dependent Neuronal Death Pathways as a Predictor of Pathogenicity for LRRK2 Mutations.
Melachroinou K et al.
Plos One, 2016
Association between Parkinson's disease and G2019S and R1441C mutations of the LRRK2 gene.
Li XX et al.
Experimental and Therapeutic Medicine, 2015
Phenotypic and molecular analyses of primary lateral sclerosis.
Mitsumoto H et al.
Neurology. Genetics, 2015
Mutation analysis of patients with neurodegenerative disorders using NeuroX array.
Ghani M et al.
Neurobiology of Aging, 2015
Parkinson's disease, genetic variability and the Faroe Islands.
Petersen MS et al.
Parkinsonism & Related Disorders, 2015
LRRK2 exonic variants and risk of multiple system atrophy.
Heckman MG et al.
Neurology, 2014
A direct interaction between leucine-rich repeat kinase 2 and specific β-tubulin isoforms regulates tubulin acetylation.
Law BM et al.
The Journal of Biological Chemistry, 2014
Identification of three novel LRRK2 mutations associated with Parkinson's disease in a Calabrian population.
Anfossi M et al.
Journal of Alzheimer's Disease : Jad, 2014
Structural and functional in silico analysis of LRRK2 missense substitutions.
Cardona F et al.
Molecular Biology Reports, 2014
Deep sequencing of the LRRK2 gene in 14,002 individuals reveals evidence of purifying selection and independent origin of the p.Arg1628Pro mutation in Europe.
Rubio JP et al.
Human Mutation, 2012